Side Effects & $2B Claims

Key Points:

• GLP-1 receptor agonist drugs like Novo Nordisk’s Ozempic, initially approved for type 2 diabetes, have surged in popularity for weight loss, with prescriptions tripling since 2020 and nearly half now prescribed for non-diabetic uses.
• This increased demand, driven by telehealth and social media, caused widespread shortages affecting diabetes patients, but the FDA declared shortages resolved by early 2025.
• Over 4,400 lawsuits have been filed alleging serious side effects such as gastrointestinal injuries, vision loss, and thyroid cancer risks, with more than 3,800 cases consolidated in federal multidistrict litigation; drugmakers deny liability and maintain safety when used as prescribed.
• Common side effects include nausea, diarrhea, and vomiting, while more severe reported issues involve gastroparesis, intestinal blockages, pancreatitis, and sudden vision loss (NAION).
• The rapid weight loss associated with these drugs has led to aesthetic concerns like "Ozempic face," characterized by facial volume loss, prompting increased demand for cosmetic procedures and sparking broader debates about weight management and cultural body image standards.